Important epidemiological and microbiological differences exist between CA- and HA-MRSA strains. Therefore, strategies to prevent and treat these infections should also differ. To prevent clinical complications from CA-MRSA, it is recommended that culturing and susceptibility testing of S. aureus clinical isolates become routine practice along with more careful selection and use of antimicrobials when treatment is indicated. MRSA isolates are NOT susceptible to beta-lactam antibiotics, however CA-MRSA infections are susceptible to some currently available non- beta-lactam antibiotics such as clindamycin and trimethoprim/sulfamethoxazole.